Harrow, Inc. (HROW) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Harrow, Inc. on September 24, 2025. The filing details the entry into a definitive Agreement and Plan of Merger to acquire the remaining equity interests of Melt Pharmaceuticals, Inc. ("Melt"), a company in which Harrow already owned approximately 45% of the outstanding equity as of June 30, 2025. The transaction was negotiated by a special committee of independent directors due to existing management relationships with Melt.
Key Financial Metrics and Transaction Structure
The filing does not provide standard financial metrics such as revenue, profit, cash flow, or debt levels for the reporting period. The primary financial data relates to the acquisition consideration for Melt:
- Initial Cash Payment: Approximately $4.3 million payable at closing.
- FDA Approval Milestone: Approximately $87.2 million in cash upon FDA approval of the MELT-300 product candidate.
- Reimbursement Milestone: Issuance of approximately 1,112,000 shares of Harrow Common Stock upon receipt of pass-through status and J-Code designation.
- Sales Milestones: Potential aggregate one-time cash payments of up to approximately $261.0 million upon achieving annual net sales milestones ranging from $100.0 million to $1.0 billion.
- Timeline: Regulatory and commercial milestones must be achieved, if at all, on or before December 31, 2035.
Material Changes
The material change reported is the transition from a non-binding Indication of Interest (IOI) announced on September 8, 2025, to a binding Merger Agreement on September 24, 2025. This agreement formalizes the acquisition of the remaining 55% of Melt's equity not already owned by Harrow.
Guidance, Risks, and Contingencies
Contingencies: The closing of the acquisition is subject to customary conditions, including approval by the requisite Melt stockholders, the accuracy of representations and warranties, and the absence of any material adverse effect. The issuance of Common Stock is contingent upon specific regulatory milestones and will be issued pursuant to Section 4(a)(2) of the Securities Act of 1933.
Risks: The filing includes standard forward-looking statement disclaimers. Risks include the failure to obtain FDA approval, failure to achieve reimbursement coding, inability to meet sales milestones, and general execution risks. The company notes that actual results may differ materially from projections.
Investor Verification Checklist
- Verify the full text of the Merger Agreement and related milestone payment agreement, expected to be filed as an exhibit to the Form 10-Q for the quarter ending September 30, 2025.
- Confirm the current status of the MELT-300 product candidate's FDA application and regulatory timeline.
- Review the specific definitions of "annual net sales" and the calculation methodology for the $261.0 million in potential sales milestones.
- Assess the dilution impact of the potential issuance of 1,112,000 shares of Common Stock upon the reimbursement milestone.
- Monitor the progress of Melt stockholder approval required to close the transaction.